Biochemical analysis of saliva in head and neck cancer patients receiving definitive chemoradiotherapy

被引:0
|
作者
Rani, Savita [1 ]
Singh, Karuna [2 ]
Paramjeet, Raja [1 ]
Banipal, Singh [3 ]
Goyal, Gitanjali [4 ]
机构
[1] Guru Gobind Singh Med Coll Hosp, Dept Radiat Oncol, Faridkot, Punjab, India
[2] Adv Canc Inst & Res Ctr, Dept Radiat Oncol, Bathinda, Punjab, India
[3] Govt Med Coll Hosp, Dept Radiat Oncol, Patiala, Punjab, India
[4] AIIMS, Dept Biochem, Bathinda, Punjab, India
关键词
Biochemical; chemoradiotherapy; head and neck; saliva; xerostomia; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; POSTOPERATIVE RADIOTHERAPY; WHOLE SALIVA; CHEMOTHERAPY; SURGERY; RISK; FRACTIONATION; STATISTICS; PHARYNGEAL;
D O I
10.4103/jcrt.jcrt_692_22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Radiation therapy leads to salivary gland damage that causes xerostomia, the standard radiation-induced complication during radiotherapy that affects the quality of life in head and neck cancer patients. This study was conducted at a tertiary cancer institute in Punjab state to analyze the influence of radiation therapy on various parameters and substances of saliva. Materials and Methods: Sixty head and neck cancer patients who underwent conventional radiotherapy on a Cobalt machine were included. Saliva was collected in both stimulated and unstimulated states. Stimulated whole saliva was collected by applying two to three drops of citric acid solution (2%) over the dorsum of the tongue bilaterally at 30-s intervals for 2 min. Biochemical changes in the whole saliva were evaluated by biochemical methods at baseline, completion of therapy, and 3 and 6 months post-radiotherapy completion. Results: The lowest concentration of proteins was seen after the therapy in unstimulated and stimulated saliva. Salivary protein levels showed a rising trend toward baseline in 3- and 6-month posttherapy samples. The peak value (0.4 mg/dl) was reached in the stimulated saliva after therapy. Salivary amylase did not show a consistent concentration graph. The salivary concentrations of sodium, potassium, and chloride showed peak values after radiotherapy. The lowest salivary pH was obtained at completion of therapy, both in unstimulated and stimulated saliva. After 3 months of chemoradiotherapy, the saliva reached a pH value of 8.3, whereas 6-month posttherapy sample showed a pH value of 8.4 in both unstimulated and stimulated saliva. Conclusions: At the completion of chemoradiotherapy, the total salivary protein, albumin, and inorganic components (calcium, magnesium, phosphorus) showed a downward trend from the baseline values due to the damage caused to the acinar part of the salivary gland by radiotherapy. The rise in salivary electrolytes' concentrations is attributed to the fact that even though there is loss of absorptive property of the tubular portion of the salivary gland, it retains its secretory property. Saliva becomes thick, scarce, tenacious, and acidic during the period of chemoradiotherapy.
引用
收藏
页码:S669 / S676
页数:8
相关论文
共 50 条
  • [1] Biochemical analysis of saliva in head and neck cancer patients receiving definitive chemoradiotherapy
    Rani, Savita
    Singh, Karuna
    Banipal, Raja Paramjeet Singh
    Goyal, Gitanjali
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 2) : S669 - S676
  • [2] Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy
    Vossen, David M.
    Verhagen, Caroline V. M.
    van der Heijden, Martijn
    Essers, Paul B. M.
    Bartelink, Harry
    Verheij, Marcel
    Wessels, Lodewyk F. A.
    van den Brekel, Michiel W. M.
    Vens, Conchita
    CANCERS, 2019, 11 (04)
  • [3] Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer
    von der Gruen, Jens Mueller
    Martin, Daniel
    Stoever, Timo
    Ghanaati, Shahram
    Roedel, Claus
    Balermpas, Panagiotis
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [4] A Reappraisal of Definitive Chemoradiotherapy for Older Adults With Advanced Head and Neck Cancer
    Smile, Timothy D.
    Reddy, Chandana A.
    Matia, Brian
    Fleming, Christopher W.
    Domb, Chaim
    Geiger, Jessica L.
    Joshi, Nikhil P.
    Woody, Neil M.
    Chute, Deborah J.
    Griffith, Christopher C.
    Adelstein, David J.
    Koyfman, Shlomo A.
    ANTICANCER RESEARCH, 2022, 42 (08) : 3845 - 3852
  • [5] Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy
    Xiao, Canhua
    Hanlon, Alexandra
    Zhang, Qiang
    Ang, Kian
    Rosenthal, David I.
    Nguyen-Tan, P. Felix
    Kim, Harold
    Movsas, Benjamin
    Bruner, Deborah Watkins
    ORAL ONCOLOGY, 2013, 49 (04) : 360 - 366
  • [6] Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis
    Aguiar, Pedro Nazareth, Jr.
    Tadokoro, Hakaru
    da Silva, Gislaine Fernandes
    Landgraf, Mayndra Mychelle
    Barreto, Carmelia Maria Noia
    Filardi, Bruno Andraus
    Lopes, Gilberto de Lima, Jr.
    Oliveira, Pedro
    de Mello, Ramon Andrade
    FUTURE ONCOLOGY, 2016, 12 (23) : 2755 - 2764
  • [7] Risk Stratification of Metastatic Neck Nodes by CT and PET in Patients with Head and Neck Cancer Receiving Definitive Radiotherapy
    Lin, Ying-Chun
    Chen, Shang-Wen
    Hsieh, Te-Chun
    Yen, Kuo-Yang
    Yang, Shih-Neng
    Wang, Yao-Ching
    Kao, Chia-Hung
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 183 - 189
  • [8] Frailty is an independent factor for health-related quality of life in patients with head and neck cancer receiving definitive concurrent chemoradiotherapy
    Lu, Chang-Hsien
    Hung, Chia-Yen
    Hsueh, Shun-Wen
    Yeh, Kun-Yun
    Hung, Yu-Shin
    Chou, Wen-Chi
    SUPPORTIVE CARE IN CANCER, 2024, 32 (02)
  • [9] Definitive Chemoradiotherapy With Carboplatin for Squamous Cell Carcinoma of the Head and Neck
    Nagasaka, Misako
    Zaki, Mark
    Issa, Majd
    Kim, Harold
    Abrams, Judith
    Sukari, Ammar
    LARYNGOSCOPE, 2017, 127 (10) : 2260 - 2264
  • [10] Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy
    Yokota, Tomoya
    Tachibana, Hiroyuki
    Konishi, Tetsuhito
    Yurikusa, Takashi
    Hamauchi, Satoshi
    Sakai, Kensuke
    Nishikawa, Masaya
    Suzuki, Miho
    Naganawa, Yayoi
    Hagihara, Tomoka
    Tsumaki, Hiromi
    Kubo, Tomo
    Sato, Maho
    Taguri, Masataka
    Morita, Satoshi
    Eguchi, Toru
    Kubota, Kaoru
    Zenda, Sadamoto
    SUPPORTIVE CARE IN CANCER, 2016, 24 (07) : 3029 - 3036